Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in endometriosis
NCT00121953Phase 3Withdrawn
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Start
- Jul 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone in endometriosis, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Primary endpoint: Peritoneal fluid cytokine concentrations. Planned start Jul 2005; status: withdrawn.
02
Drugs
rosiglitazone
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT00121953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121953.